Source: ERJ Open Res, 7 (1) 00787-2020; 10.1183/23120541.00787-2020
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
Lars Hagmeyer, Stephan Schäfer, Marianne Engels, Anja Pietzke-Calcagnile, Marcel Treml, Simon-Dominik Herkenrath, Matthias Heldwein, Khosro Hekmat, Sandhya Matthes, Andreas Scheel, Jürgen Wolf, Reinhard Büttner, Winfried Randerath. High sensitivity of PD-L1 analysis from pleural effusion in nonsmall cell lung cancer. ERJ Open Res, 7 (1) 00787-2020; 10.1183/23120541.00787-2020

Member's Comments

No comment yet.

Related content which might interest you: Sensitivity of PD-L1 analysis from pleural effusion in non-small cell lung cancer Source: Virtual Congress 2020 – Novel directions in pleural disease: bench to bedside Year: 2020 Oncodrivers in malignant pleural effusions associated with non-small cell lung cancer Source: Virtual Congress 2020 – Interventional pulmonology: the pleura and bronchoscopic treatment of emphysema Year: 2020 Diagnostic significance of ADAM8 in non-small cell lung cancer and malignant pleural effusion Source: Annual Congress 2008 - Diagnostic aspects in thoracic oncology Year: 2008 Hypotonic carboplatin pleurodesis for malignant pleural effusion of non-small cell lung cancer Source: Eur Respir J 2002; 20: Suppl. 38, 273s Year: 2002 Evaluation of dendritic cells in peripheral blood and pleural effusion of non-small-cell lung cancer patients Source: Eur Respir J 2004; 24: Suppl. 48, 529s Year: 2004 Survival of lung adenocarcinoma patients with malignant pleural effusion Source: Eur Respir J 2013; 41: 1409-1418 Year: 2013 Features of N-staging in left-sided non-small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 719s Year: 2006 PD-L1 determination in cytological and histological samples in patients with non-small cell lung cancer Source: International Congress 2018 – Linear and radial EBUS and peripheral nodules Year: 2018 Possibility of the specific efficacy of gefitinib for miliary lung metastasis in non-small cell lung cancer Source: Eur Respir J 2004; 24: Suppl. 48, 303s Year: 2004 Detecting extrathoracic metastases in patients with non-small cell lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 41s Year: 2006 Factors affecting the prognosis of nonsmall cell lung cancer with chest wall-parietal pleural invasion (T3) following resection Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010 Role of EBUS-TBNA in the study of PD-L1 expression in patients with non-small cell lung cancer (NSCLC) Source: Virtual Congress 2020 – Endobronchial ultrasound: from rookie to pro Year: 2020 Bronchoscopic intratumoural therapies for non-small cell lung cancer Source: Eur Respir Rev, 29 (156) 200028; 10.1183/16000617.0028-2020 Year: 2020 Biological characteristics of dendritic cells from malignant pleural effusions in patients with lung cancer Source: Eur Respir J 2006; 28: Suppl. 50, 772s Year: 2006 RNA is favourable for analysing EGFR mutations in malignant pleural effusion of lung cancer Source: Eur Respir J 2012; 39: 677-684 Year: 2012 Visceral pleural invasion is an invasive and aggressive indicator of nonsmall cell lung cancer Source: ISSN=ISSN 1810-6838, ISBN=, page=264 Year: 2006 An update on treatment of malignant pleural effusion with or without known primary bronchial adenocarcinoma Source: Annual Congress 2006 - Medical and surgical management of malignant pleuritis Year: 2006 Efficacy of EGFR-TKI for malignant pleural effusion in lung adenocarcinoma patients Source: International Congress 2017 – Mesothelioma and malignant pleural disease Year: 2017 Soluble non-invasive markers in non-small cell lung cancer Source: Eur Respir J 2005; 26: Suppl. 49, 459s Year: 2005 The expression of PD-1 on CD8+ T cells in malignant pleural effusion of lung cancer and its associated significance Source: Annual Congress 2010 - Current issues in malignant pleural diseases Year: 2010